Clinical response (e.g., necrosis or tumour reduction) was observed in 16 of 17 patients, except for patient 10 (advanced ER-/HER2+ breast cancer recurrence, see Figure 4B). This evidence concerns the gene ERBB2 and breast carcinoma.